Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Fava

Showing results (51-60 of 799) with videos related to

Pageof 80
Sort By:
The American Journal of Psychiatry|February 4, 2003
Depression, IV: STAR*D treatment trial for depressionA John Rush, Madhukar Trivedi, Maurizio Fava
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 12, 2010
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorderGeorge I Papakostas, Dana Charles, Maurizio Fava
The Psychiatric Clinics of North America|March 17, 2007
A critical overview of the pharmacologic management of treatment-resistant depressionAndrew A Nierenberg, Judith Katz, Maurizio Fava
Translational Psychiatry|April 29, 2023
Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placeboRoberto Gomeni, Françoise Bressolle-Gomeni, Maurizio Fava
Journal of Clinical Pharmacology|January 27, 2018
Is It Time for Going Beyond the P-Value Paradigm With the Estimation of the Probability of Clinical Benefit as a Criterion for Assessing the Outcomes of a Clinical Trial? A Case Study in Patients With Major Depressive DisorderRoberto Gomeni, Françoise Bressolle-Gomeni, Maurizio Fava
Molecular Psychiatry|June 25, 2026
Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventionsClotilde Guidetti, Maurizio Fava, George I Papakostas
Journal of Biopharmaceutical Statistics|February 23, 2019
A commentary on: statistical inference problems in sequential parallel comparison designsDavid Alan Schoenfeld, Gheorghe Doros, Maurizio Fava
The Journal of Clinical Psychiatry|May 1, 2009
Closing the efficacy-effectiveness gap: translating both the what and the how from randomized controlled trials to clinical practiceAnthony P Weiss, Jenny Guidi, Maurizio Fava
Current Psychiatry Reports|May 15, 2004
Impact of medical comorbid disease on antidepressant treatment of major depressive disorderDan V Iosifescu, Bettina Bankier, Maurizio Fava
Psychiatry Research|August 6, 2023
A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligenceRoberto Gomeni, Françoise Bressolle-Gomeni, Maurizio Fava
Pageof 80

Showing results (51-60 of 799) with videos related to

Sort By:
Pageof 80
The American Journal of Psychiatry|February 4, 2003
Depression, IV: STAR*D treatment trial for depressionA John Rush, Madhukar Trivedi, Maurizio Fava
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 12, 2010
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorderGeorge I Papakostas, Dana Charles, Maurizio Fava
The Psychiatric Clinics of North America|March 17, 2007
A critical overview of the pharmacologic management of treatment-resistant depressionAndrew A Nierenberg, Judith Katz, Maurizio Fava
Translational Psychiatry|April 29, 2023
Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placeboRoberto Gomeni, Françoise Bressolle-Gomeni, Maurizio Fava
Journal of Clinical Pharmacology|January 27, 2018
Is It Time for Going Beyond the P-Value Paradigm With the Estimation of the Probability of Clinical Benefit as a Criterion for Assessing the Outcomes of a Clinical Trial? A Case Study in Patients With Major Depressive DisorderRoberto Gomeni, Françoise Bressolle-Gomeni, Maurizio Fava
Molecular Psychiatry|June 25, 2026
Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventionsClotilde Guidetti, Maurizio Fava, George I Papakostas
Journal of Biopharmaceutical Statistics|February 23, 2019
A commentary on: statistical inference problems in sequential parallel comparison designsDavid Alan Schoenfeld, Gheorghe Doros, Maurizio Fava
The Journal of Clinical Psychiatry|May 1, 2009
Closing the efficacy-effectiveness gap: translating both the what and the how from randomized controlled trials to clinical practiceAnthony P Weiss, Jenny Guidi, Maurizio Fava
Current Psychiatry Reports|May 15, 2004
Impact of medical comorbid disease on antidepressant treatment of major depressive disorderDan V Iosifescu, Bettina Bankier, Maurizio Fava
Psychiatry Research|August 6, 2023
A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligenceRoberto Gomeni, Françoise Bressolle-Gomeni, Maurizio Fava
Pageof 80